<unk>  is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Belantamab mafodotin
Brexucabtagene autoleucel
Ciltacabtagene autoleucel
Enadenotucirev
Baloxavir marboxil
Idecabtagene vicleucel
Trenbolone hexahydrobenzylcarbonate
Valoctocogene roxaparvovec